Breast cancer is the most frequent malignancy in women worldwide and is curable in~ 70–
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …

Globally, breast cancer is the most common cancer type and is one of the most significant
causes of deaths in women. To date, multiple clinical interventions have been applied …

The discovery of oestrogen receptor β (ERβ/ESR2) was a landmark discovery. Its reported
expression and homology with breast cancer pharmacological target ERα (ESR1) raised …

The activation of nuclear factor-kappaB (NFΚB), a proinflammatory transcription factor, is a
commonly observed phenomenon in breast cancer. It facilitates the development of a …

AIM: Analyzing the presentation of molecular subtypes of breast cancer that are
immunohistochemically detected in surgically treated patients at the Clinic for Thoracic and …

Selective estrogen receptor modulators (SERMs) are compounds that exhibit tissue-specific
estrogen receptor (ER) agonist or antagonist activity, and are used for various indications …

The aim of this study was to investigate the expression levels of methylenetetrahydrofolate
dehydrogenase (NADP+-dependent) 2 (MTHFD2) and the associated clinical implications in …

Millions of putative transcriptional regulatory elements (TREs) have been cataloged in the
human genome, yet their functional relevance in specific pathophysiological settings …

More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and
resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor …

Background: Silibinin (SB), the main component of Silymarin (SM), is a natural substance
obtained from the seeds of the milk thistle. SM contains up to 70% of SB as two isoforms: A …